enGene Therapeutics expected to report 43-cent-a-share loss
TradingView News preview says enGene Therapeutics Inc. is expected to post a loss of 43 cents a share.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.